Abstract:Aims of the study Blood coagulation parameters are colossally important for clinical evaluation of palliative chemotherapy; however, this niche was not explored earlier for advanced-stage non-small cell lung cancer (NSCLC). Study focuses to explore the clinical relevancy of Coagulation parameters; prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (FIB), D-dimer and international normalised ratio (INR) and their response to palliative chemotherapy in advanced-stage NSCLC. Methods A retrospective study was conducted between 2013 and 2019 in Jiangsu Cancer hospital, Nanjing, PR. China. Medical records of 5445 patients were succinctly reviewed and classified accordingly to the inclusion and exclusion criteria. A total of 216 advanced NSCLC patients who used a first-line chemotherapy and antiangiogenic therapy regimen were enrolled in this study under ethical approval (JSCH-2020C-009). Blood samples were collected from these patients to measure the response levels of these coagulation parameters at time of admission to hospital and at the beginning of 4 cycles of Palliative therapy. We find the clinical value of all these coagulation parameters by using SPSS 24. Univariate Cox regression and Multivariate Cox regression models were used to identify the factors that were associated with progression-free survival (PFS) and the response to palliative chemotherapy. Results In the Kaplan-Meier survival analysis for overall median (95% CI) survival of high pre-treatment coagulation parameters showed shorter PFS compared with normal pre-treatment except TT and their overall median (95% CI) follow-up was 3.3 (3.12-3.47). Coagulation parameters have showed clinical relevance as a potential independent prognostic factor of PFS in the Univariate Cox regression. In multivariable model, Age (>= 60 years vs < 60 years), cancer differentiation (Unknown vs Poor), PT (High vs Normal) range, FIB (High vs Normal) range and D-dimer (High vs Normal) range, (P = .025,P = .045,P = .029,P = .049 andP = .011, respectively) were associated as a prognostic factor of PFS in NSCLC. Patients on 3-drugs regimen found to have better PFS compared with the ones taking the 2-drugs treatment regimen (P = .043). Conclusion The high range of PT, FIB and D-dimers was associated with poor prognosis of advanced-stage NSCLC. Our findings also confirmed that patients on 3-drugs regimen showed longer PFS compared with 2-drugs regimen.

Imbalance Of Pro- Vs. Anti-Coagulation Factors In Chinese Patients With Budd-Chiari Syndrome And Non-Cirrhotic Portal Vein Thrombosis

Coagulation imbalance may not contribute to the development of portal vein thrombosis in patients with cirrhosis.

Prevalence of Prothrombotic Factors in Patients with Budd-Chiari Syndrome or Non-Cirrhotic Nonmalignant Portal Vein Thrombosis: A Hospital-Based Observational Study.

Polymorphisms in the Genes for Coagulation Factor II, V, VII in Patients Undergoing Coronary Angiography

Thrombotic risk factors in Chinese Budd-Chiari syndrome patients. An observational study with a systematic review of the literature.

Prevalence of Paroxysmal Nocturnal Hemoglobinuria in Chinese Patients with Budd‐Chiari Syndrome or Portal Vein Thrombosis

Difference in Budd‐Chiari syndrome between the west and china

The detection of prothrombin time in patients with Budd-Chiari syndrome and the clinical significance

Review article: the aetiology of primary Budd–Chiari syndrome – differences between the West and China

Prevalence of Inherited Antithrombin, Protein C, and Protein S Deficiencies in Portal Vein System Thrombosis and Budd‐Chiari Syndrome: A Systematic Review and Meta‐analysis of Observational Studies

Relation of Iodine Level of Drinking Water and Coagulation in Patients with Membrane Obstruction of Inferior Vena Cava in Budd-Chiarri Syndrome

The analysis of activities of vitamin K-dependent coagulation factors, protein C and protein S in patients on war- farin therapy

Study on Clinical Features and Etiology of Primary Budd-Chiari Syndrome

Clinical Features of Patients with Budd-Chiari Syndrome Caused by Hepatic Vein Thrombosis

Study on Blood Coagulant/Fibrinolytic Activity at Plasma and Monocytic Levels in Coronary Heart Disease Patients Withblood-Stasis Syndrome of Traditional Chinese Medicine

Effect of antithrombin, protein C and protein S on portal vein thrombosis in liver cirrhosis: a meta-analysis.

[Clinical Significance of Anticoagulant Proteins Detection in Patients with Thrombotic Events].

Scientific Publications on Portal Vein Thrombosis and Budd-Chiari Syndrome: a Global Survey of the Literature.

Coagulation profile and platelet function in patients with extrahepatic portal vein obstruction and non-cirrhotic portal fibrosis

The function regulation of protein C system and novel high risk of venous thrombosis

Clinical Evaluation Of Plasma Coagulation Parameters In Patients With Advanced-Stage Non-Small Cell Lung Cancer Treated With Palliative Chemotherapy In China